Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nevirapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nevirapine SCHEMBL29614675 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL29393780 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL3232525 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL30267890 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL3318 | 0.99 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL1923903 | 0.98 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL6562884 | 0.98 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL8151939 | 0.98 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL9704195 | 0.94 | ALDH1A1 (0.91) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL28679264 | 0.93 | ALDH1A1 (0.89) | ALDH1A1LMNAPOLBADORA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642089-B2 | Melt extrusion of salts of active ingredients | EVONIK ROEHM GMBH (DE) | 2014-02-04 | — | — | US | claimed |
| EP-1478344-B1 | MELT EXTRUSION CONSISTING OF SALTS OF ACTIVE INGREDIENTS | ROEHM GMBH (DE) | 2007-05-23 | — | — | EP | claimed |
| US-20040253314-A1 | Melt extrusion of salts of active ingredients | ROEHM GMBH (DE) | 2004-12-16 | — | — | US | claimed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115315435-A | IL-7R alpha gamma c binding compounds | 麦地金公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-115297886-A | IL-7R alpha binding compounds | 麦地金公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113891714-A | Triple therapy to enhance cancer cell killing in low immunogenic cancers | 大连万春布林医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-113543806-A | Drug delivery combining epigenetic regulation and immune checkpoint blockade | 北卡罗莱纳州立大学 | 2021-10-22 | — | — | CN | disclosed |
| CN-112955162-A | Adipocyte-mediated delivery of anticancer therapeutics | 北卡罗莱纳州立大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-112930198-A | Compositions and methods for organ-specific delivery of nucleic acids | 德克萨斯大学系统董事会 | 2021-06-08 | — | — | CN | disclosed |
| CN-112040951-A | Antibody Drug Conjugates (ADC) with NAMPT inhibitors | 拜耳股份公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-111565632-A | System and microtubule conductivity for characterizing, diagnosing and treating a health condition of a patient and methods of use thereof | 奥特美医疗有限责任公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |
| US-8642089-B2 | Melt extrusion of salts of active ingredients | EVONIK ROEHM GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20040253314-A1 | Melt extrusion of salts of active ingredients | ROEHM GMBH (DE) | 2004-12-16 | — | — | US | disclosed |